A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when given to people with liver problems

2023-503415-15-00 Protocol DCC-3014-01-004 Human pharmacology (Phase I) - Other Ended

Start 21 Dec 2023 · End 6 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol DCC-3014-01-004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 1
Sites 1

Tenosynovial Giant Cell Tumor (TGCT)

Key facts

Sponsor
Deciphera Pharmaceuticals Inc.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
21 Dec 2023 → 6 Dec 2025
Decision date (initial)
2023-09-15
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Tenosynovial Giant Cell Tumor (TGCT)

VersionLevelCodeTermSystem organ class
21.0 LLT 10018253 Giant cell tumor of tendon sheath 10029104
21.1 PT 10010014 Colony stimulating factor therapy 100000004865
21.1 PT 10018255 Giant cell tumour of tendon sheath 100000004864
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Deciphera Pharmaceuticals Inc.

Sponsor organisation
Deciphera Pharmaceuticals Inc.
Address
200 Smith Street
City
Waltham
Postcode
02451-0099
Country
United States

Scientific contact point

Organisation
Deciphera Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Public contact point

Organisation
Deciphera Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 32 1
Rest of world
United States
16

Investigational sites

Hungary

1 site · Ended
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2023-12-21 2025-12-05 2023-12-27 2025-12-05

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-06-22 Hungary Acceptable
2023-09-13
2023-09-15
2 SUBSTANTIAL MODIFICATION SM-1 2023-11-20 Hungary Acceptable
2023-12-11
2023-12-20